Thus, beyond their use in monogenic inborn errors of the JAK-STAT pathway [28], the benefit of JAK inhibition in the treatment of autoimmune cytopenias seen in the context of interferon-related diseases, such as systemic lupus erythematosus, deserves consideration. The gene discussed is SOAT1; the disease is systemic lupus erythematosus.